Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Employees - 6900, CEO - Mr. Kevin T. Conroy J.D., Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 0.94, Piotroski Score(max is 10): 4, Working Capital: $867876000, Total Assets: $5711073000, Retained Earnings: $-4599247000, EBIT: -1025063000, Total Liabilities: $3314166000, Revenue: $2828128000

AryaFin Target Price - $-37.71 - Current Price $ - Analyst Target Price $